Page last updated: 2024-12-07

3-acetylpyridine adenine dinucleotide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID123926
CHEBI ID166857
MeSH IDM0047827

Synonyms (38)

Synonym
3-acetyl-1-[(2r,3r,4s,5r)-5-{[({[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphorylphosphonato)oxy]methyl}-3,4-dihydroxyoxolan-2-yl]-1lambda(5)-pyridin-1-ylium
CHEBI:166857
acetylpyridine-adenine dinucleotide
3-acetyl nad
acpyad
(3-acetylpyridine)ad
3-acetylpyridine-adenine dinucleotide
3-acetylpyridineadenine dinucleotide
acetylpyridine adenine dinucleotide
3-acetylpyridine nad
86-08-8
3-acetylpyridine-dpn
3-acetylpyridine adenine dinucleotide
nicotinamide acetylpyridine dinucleotide
3-acetylpyridine-nad
[(2r,3s,4r,5r)-5-(3-acetylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphate
adenosine 5'-(trihydrogen diphosphate), 5'-5'-ester with 3-acetyl-1-beta-d-ribofuranosylpyridinium hydroxide, inner salt
nsc 20275
beta-3-acetylpyridine adenine dinucleotide
3-acetylpyridine diphosphopyridine nucleotide (van)
3-acetyl-1-beta-d-ribofuranosylpyridinium hydroxide 5'ester
einecs 201-649-4
apad
AKOS015892306
3-acetylpyridine adenine dinucleotide, oxidised form 92+%
mfcd00078882
3-acetylpyridine adenine dinucleotide, oxidised form
Z3234879531
3-acetyl-1-((2r,3r,4s,5r)-5-((((((((2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)oxy)oxidophosphoryl)oxy)methyl)-3,4-dihydroxytetrahydrofuran-2-yl)pyridin-1-ium
3-acetyl-1-((2r,3r,4s,5r)-5-((((((2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryloxy)oxidophosphoryloxy)methyl)-3,4-dihydroxytetrahydrofuran-2-yl)pyridinium
DTXSID901018980
apad, oxidized
3-acetylpyridineadeninedinucleotide
CS-0135909
PD057552
3-acetyl-1-[(2r,3r,4s,5r)-5-{[({[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl phosphonato)oxy]methyl}-3,4-dihydroxyoxolan-2-yl]-1-pyridin-1-ylium
F73777
HY-131485
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (67)

TimeframeStudies, This Drug (%)All Drugs %
pre-199021 (31.34)18.7374
1990's34 (50.75)18.2507
2000's10 (14.93)29.6817
2010's2 (2.99)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.68 (24.57)
Research Supply Index4.23 (2.92)
Research Growth Index4.28 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other68 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]